IO BIOTECH, INC.
IO Biotech, Inc. (IOBT) is a small-cap, clinical-stage biotechnology company that focuses on developing immunotherapies for cancer. With a market capitalisation near $67.2m, it sits in the higher-risk, catalyst-driven corner of the market: clinical trial results, regulatory decisions and partnership news tend to be the main drivers of value. Investors should be aware that outcomes are often binary — positive data can materially improve prospects while negative results can sharply reduce valuation. Smaller biotech companies commonly need additional funding as they progress programmes, which can lead to dilution. Trading volumes may be limited, increasing price volatility. This summary is educational and not personalised investment advice. Consider your risk tolerance, time horizon and seek independent advice if unsure. Past performance is not a reliable indicator of future results, and biotech investments can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying IO Biotech's stock with a target price of $2.46, indicating strong potential growth.
Financial Health
IO Biotech is generating modest cash flow but has a very low book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IOBT
Pharma's Private Equity Pivot: The Immunology Opportunity
Bristol Myers Squibb has partnered with Bain Capital to launch a new immunology-focused firm, highlighting a trend of pharma giants spinning out assets with private equity backing. This creates an investment opportunity in specialized biotech companies and the broader drug development ecosystem that supports them.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Catalyst-driven stock
Clinical trial results and regulatory milestones can sharply move valuation; outcomes are binary and volatility is common.
Therapy development focus
Progress in clinical data may open partnership or licensing opportunities, though development setbacks and delays are possible.
Industry context
Operates in a competitive oncology landscape where funding, regulation and rival programmes shape prospects; consider liquidity and dilution risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
